Adamis Reports APC-300 Kills Human Pancreatic Cancer Cells

SAN DIEGO--()--Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced today that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells. Pancreatic cancer still remains one of the most deadly forms of all cancers. The mortality from pancreatic cancer compares strikingly with its incidence. It has one of the worst prognoses with an overall survival rate of less than 5% and with most of the patients dying within the first two years. Recent results regarding the mechanism leading to the occurrence of pancreatic cancer suggest that in more than 90% of pancreatic cancers the Ras oncogene has been mutated. The mutation of the Ras oncoprotein has been linked to the induction of multiple signaling pathways within the cell which leads to the resistance of those cells to apoptosis (cell death) and the emergence of cancer.

In an attempt to understand how APC-300 works, Dr. Hasan Mukhtar and his team at the University of Wisconsin, have taken human pancreatic adenocarcinoma cells and investigated the effect of APC-300 on tumor cell growth and on the modulation of multiple Ras induced signaling pathways. APC-300 treatment of cancer cells was found to significantly reduce the expression of Ras oncoprotein and to modulate the protein expression of various signaling molecules involved in cancer cell growth. APC-300 attacks the cancer cells at multiple signaling pathways leading to tumor cell death and the inhibition of the growth of pancreatic cancer cells (Life Sciences, 2011 (88) pp. 285-293 and Cancer Res. 2009, 69(3) 1156-65.).

Additionally, in a mouse pancreatic cancer model, APC-300 was shown to significantly reduce the growth of tumors (p<0.01). Collectively, the data show that APC-300 induces apoptosis leading to the reduced tumorgenicity of human pancreatic cancer cells in the mouse tumor model and the killing of cancer cells in vitro. It is believed that one of the advantages of APC-300 is that it has the ability to intervene at more than one critical pathway in the pancreatic cancer cell process.

Dr. Dennis J. Carlo, Ph.D., President and CEO of Adamis states that, “Because of the known mechanisms of action of APC-300, and its ability to effect multiple signaling targets within the cancer cell, this drug will likely be active against different tumors. In fact, the data we have to date, support that to be the case.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals has two wholly-owned subsidiaries: Adamis Laboratories and Adamis Therapeutics Inc. (formerly Adamis Viral Therapies). Adamis Labs has niche prescription products in the allergy and respiratory therapeutic area and intends to launch additional products in this area. Currently, Adamis Therapeutics is primarily focused on the development of patented, proprietary technologies for the potential treatment of human prostate cancer.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future performance, including, but not limited to the following statements: the company’s beliefs concerning the effectiveness of APC-300; the results of any future clinical trials that the company may conduct relating to APC-300; the ability to fund future product development; assuming it is developed and approved for marketing by the FDA and other regulatory authorities; and the intellectual property protection that may be afforded by any patents or patent applications relating to APC-300. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. Certain other risks, uncertainties, and other factors, as well as other risks and uncertainties relating to the company’s business are described in greater detail in Adamis’ filings from time to time with the SEC, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

Contacts

Capital Group Communications, Inc.
Mark Bernhard mark@capitalgc.com or
Mark Gundy mark.gundy@capitalgc.com
415.332.7200
or
Equititrend
Brian Barnes
bbarnes@equititrend.com
1-800-953-3350

Contacts

Capital Group Communications, Inc.
Mark Bernhard mark@capitalgc.com or
Mark Gundy mark.gundy@capitalgc.com
415.332.7200
or
Equititrend
Brian Barnes
bbarnes@equititrend.com
1-800-953-3350